Metabolic symbiosis in cancer: Refocusing the Warburg lens

Molecular Carcinogenesis

Volumn 52, Issue 5, 2013, Pages 329-337

  Nakajima, Erica C ^a   Van Houten, Bennett ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Glycolysis; Lactate; Metabolic symbiosis; Metabolism; Mitochondria; Warburg

Indexed keywords

GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ACIDIFICATION; ARTICLE; CELL RESPIRATION; DOWN REGULATION; ENZYME ACTIVITY; FERMENTATION; GLYCOLYSIS; HUMAN; HYPOXIA; MANOMETER; METABOLISM; MITOCHONDRION; NEOPLASM; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SYMBIOSIS;

ADENOSINE TRIPHOSPHATE; CELL HYPOXIA; ENERGY METABOLISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; LACTATE DEHYDROGENASES; LACTATES; MUTATION; NEOPLASMS; ONCOGENES; PHOSPHORYLATION;

EID: 84876115558     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21863     Document Type: Article

References (105)

1. Warburg O. Origin of cancer cells. Science 1956; 123: 309-314.
2. Godinot C, de Laplanche E, Hervouet E, Simonnet H. Actuality of Warburg's views in our understanding of renal cancer metabolism. J Bioenerg Biomembr 2007; 39: 235-241.
3. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008; 134: 703-707.
4. Samudio I, Fiegl M, Andreeff M. Mitochondrial uncoupling and the Warburg effect: Molecular basis for the reprogramming of cancer cell metabolism. Cancer Res 2009; 69: 2163-2166.
5. Sun QA, Chen XX, Ma JH, et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 2011; 108: 4129-4134.
6. Wolf A, Agnihotri S, Micallef J, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 2011; 208: 313-326.
7. Minchenko A, Leshchinsky I, Opentanova I, et al. Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase-3 (PFKFB3) gene-Its possible role in the Warburg effect. J Biol Chem 2002; 277: 6183-6187.
8. Zu XL, Guppy M. Cancer metabolism: Facts, fantasy, and fiction. Biochem Biophys Res Commun 2004; 313: 459-465.
9. Stern R, Shuster S, Neudecker BA, Fromby B. Lactate stimulates fibroblast expression of hyaluronan and CD44: The Warburg effect revisited. Exp Cell Res 2002; 276: 24-31.
10. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891-899.
11. Helmlinger G, Schell A, Dellian M, Forbes NS, Jain RK. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res 2002; 8: 1284-1291.
12. De Milito A, Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol 2005; 1: 779-786.
13. Perez-Sayans M, Manuel Somoza-Martin J, Barros-Angueira F, Gandara Rey JM, Garcia-Garcia A. V-ATPase inhibitors and implication in cancer treatment. Cancer Treat Rev 2009; 35: 707-713.
14. Gertz EW, Wisneski JA, Stanley WC, Neese RA. Myocardial substrate utilization during exercise in humans-dual carbon-labeled carbohydrate isotope experiments. J Clin Invest 1988; 82: 2017-2025.
15. Brooks GA. Lactate shuttles in nature. Biochem Soc Trans 2002; 30: 258-264.
16. Hashimoto T, Hussien R, Cho HS, Kaufer D, Brooks GA. Evidence for the mitochondrial lactate oxidation complex in rat neurons: Demonstration of an essential component of brain lactate shuttles. PLoS ONE 2008; 3: e2915, 1-8.
17. Magistretti PJ. Neuron-glia metabolic coupling plasticity. J Exp Biol 2006; 209: 2304-2311.
18. Fliss MS, Usadel H, Caballero OL, et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 2000; 287: 2017-2019.
19. Polyak K, Li Y, Zhu H, et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 1998; 20: 291-293.
20. Brandon M, Baldi P, Wallace DC. Mitochondrial mutations in cancer. Oncogene 2006; 25: 4647-4662.
21. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
22. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: Metabolism and tumor cell growth. Curr Opin Genet Dev 2008; 18: 54-61.
23. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010; 330: 1340-1344.
24. Weinhouse S. Respiratory impairment in cancer cells. Science 1956; 124: 267-269.
25. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11: 85-95.
26. Sonveaux P, Vegran F, Schroeder T, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008; 118: 3930-3942.
27. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, et al. Ketones and lactate "fuel" tumor growth and metastasis Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 2010; 9: 3506-3514.
28. Migneco G, Whitaker-Menezes D, Chiavarina B, et al. Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis Evidence for stromal-epithelial metabolic coupling. Cell Cycle 2010; 9: 2412-2422.
29. Lu X, Kang YB. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010; 16: 5928-5935.
30. Vleugel MM, Greijer AE, Shvarts A, et al. Differential prognostic impact of hypoxia induced and diffuse HIF-1 alpha expression in invasive breast cancer. J Clin Pathol 2005; 58: 172-177.
31. Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC, Xavier RJ. An integrative genomics approach identifies hypoxia inducible factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res 2009; 37: 4587-4602.
32. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3: 177-185.
33. Luo W, Hu H, Chang R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011; 145: 732-744.
34. Wheaton WW, Chandel NS. Hypoxia. 2. Hypoxia regulates cellular metabolism. Am J Physiol Cell Physiol 2011; 300: C385-C393.
35. Wilson DF, Erecinska M, Drown C, Silver IA. Effect of oxygen tension on cellular energetics. Am J Physiol 1977; 233: C135-C140.
36. Wilson DF, Rumsey WL, Green TJ, Vanderkooi JM. The oxygen dependence of mitochondrial oxidative phosphorylation measured by a new optical method for measuring oxygen concentration. J Biol Chem 1988; 263: 2712-2718.
37. Yu JL, Rak JW, Carmeliet P, Nagy A, Kerbel RS, Coomber BL. Heterogeneous vascular dependence of tumor cell populations. Am J Pathol 2001; 158: 1325-1334.
38. Pigott KH, Hill SA, Chaplin DJ, Saunders MI. Microregional fluctuations in perfusion within human tumours detected using laser Doppler flowmetry. Radiother Oncol 1996; 40: 45-50.
39. Mayer A, Hockel M, Horn LC, Schmidberger H, Vaupel P. GLUT-1 staining of squamous cell carcinomas of the uterine cervix identifies a novel element of invasion. Int J Oncol 2011; 38: 145-150.
40. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674.
41. de Moura MB, dos Santos LS, Van Houten B. Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ Mol Mutagen 2010; 51: 391-405.
42. Gottlieb E, Tomlinson IP. Mitochondrial tumour suppressors: A genetic and biochemical update. Nat Rev Cancer 2005; 5: 857-866.
43. Ramanathan A, Wang C, Schreiber SL. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci USA 2005; 102: 5992-5997.
44. Manning BD, Cantley LC. AKT/PKB signaling: Navigating downstream. Cell 2007; 129: 1261-1274.
45. Matoba S, Kang JG, Patino WD, et al. p53 regulates mitochondrial respiration. Science 2006; 312: 1650-1653.
46. Gottlieb E, Vousden KH. p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol 2010; 2: a001040.
47. Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126: 107-120.
48. Mor I, Cheung EC, Vousden KH. Control of glycolysis through regulation of PFK1: Old friends and recent additions. Cold Spring Harb Symp Quant Biol 2011; LXXVI (in press).
49. Dang CV. MYC, microRNAs and glutamine addiction in cancers. Cell Cycle (Georgetown, TX) 2009; 8: 3243-3245.
50. Samper E, Morgado L, Estrada JC, et al. Increase in mitochondrial biogenesis, oxidative stress, and glycolysis in murine lymphomas. Free Radic Biol Med 2009; 46: 387-396.
51. Li F, Wang Y, Zeller KI, et al. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol 2005; 25: 6225-6234.
52. Graves JA, Rothermund K, Wang T, Qian W, Van Houten B, Prochownik EV. Point mutations in c-Myc uncouple neoplastic transformation from multiple other phenotypes in rat fibroblasts. PLoS ONE 2010; 5: e13717.
53. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470: 214-220.
54. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899-905.
55. Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464: 999-1005.
56. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101-106.
57. Murray CM, Hutchinson R, Bantick JR, et al. Monocarboxylate transporter MCT1 is a target for immunosuppression. Nat Chemi Biol 2005; 1: 371-376.
58. Basanta D, Scott JG, Rockne R, Swanson KR, Anderson AR. The role of IDH1 mutated tumour cells in secondary glioblastomas: An evolutionary game theoretical view. Phys Biol 2011; 8: 015016.
59. Reitman ZJ, Jin G, Karoly ED, et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci USA 2011; 108: 3270-3275.
60. Yan H, Bigner DD, Velculescu V, Parsons DW. Mutant metabolic enzymes are at the origin of gliomas. Cancer Res 2009; 69: 9157-9159.
61. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-744.
62. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225-234.
63. Chowdhury R, Yeoh KK, Tian YM, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 2011; 12: 463-469.
64. Prensner JR, Chinnaiyan AM. Metabolism unhinged: IDH mutations in cancer. Nat Med 2011; 17: 291-293.
65. Yun JY, Rago C, Cheong I, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009; 325: 1555-1559.
66. Gaglio D, Metallo CM, Gameiro PA, et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol 2011; 7: 523.
67. Wise DR, Thompson CB. Glutamine addiction: A new therapeutic target in cancer. Trends Biochem Sci 2010; 35: 427-433.
68. Weinberg F, Hamanaka R, Wheaton WW, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 2010; 107: 8788-8793.
69. Avril N, Menzel M, Dose J, et al. Glucose metabolism of breast cancer assessed by F-18-FDG PET: Histologic and immunohistochemical tissue analysis. J Nucl Med 2001; 42: 9-16.
70. Westerterp M, Sloof GW, Hoekstra OS, et al. (18)FDG uptake in oesophageal adenocarcinoma: Linking biology and outcome. J Cancer Res Clin Oncol 2008; 134: 227-236.
71. Rossignol R, Gilkerson R, Aggeler R, Yamagata K, Remington SJ, Capaldi RA. Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res 2004; 64: 985-993.
72. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 2007; 104: 19345-19350.
73. Liu YY, Zuckier LS, Ghesani NV. Dominant uptake of fatty acid over glucose by prostate cells: A potential new diagnostic and therapeutic approach. Anticancer Res 2010; 30: 369-374.
74. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 2006; 9: 230-234.
75. Yamada Y, Nakamura K, Aoki S, et al. Lactate dehydrogenase, Gleason score and HER-2 overexpression are significant prognostic factors for M1b prostate cancer. Oncol Rep 2011; 25: 937-944.
76. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. Lactate dehydrogenase 5 expression in operable colorectal cancer: Strong association with survival and activated vascular endothelial growth factor pathway-A report of the tumour angiogenesis research group. J Clin Oncol 2006; 24: 4301-4308.
77. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group. J Clin Oncol 2006; 24: 4738-4745.
78. Kim KB, Sosman JA, Fruehauf JP, et al. BEAM: A randomized phase II study evaluating the activity of BEvacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2011; (in press).
79. Danner BC, Didilis VN, Wiemeyer S, et al. Long-term survival is linked to serum LDH and partly to tumour LDH-5 in NSCLC. Anticancer Res 2010; 30: 1347-1351.
80. Brizel DM, Schroeder T, Scher RL, et al. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 51: 349-353.
81. Quistorff B, Grunnet N. The isoenzyme pattern of LDH does not play a physiological role; except perhaps during fast transitions in energy metabolism. Aging US 2011; 3: 457-460.
82. Gladden LB. 200th anniversary of lactate research in muscle. Exerc Sport Sci Rev 2008; 36: 109-115.
83. Van Hall G. Lactate as a fuel for mitochondrial respiration. Acta Physiol Scand 2000; 168: 643-656.
84. Brooks GA. Cell-cell intracellular lactate shuttles. J Physiol 2009; 587: 5591-5600.
85. Granchi C, Bertini S, Macchia M, Minutolo F. Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr Med Chem 2010; 17: 672-697.
86. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic-enzymes by hypoxia-inducible factor-1. J Biol Chem 1994; 269: 23757-23763.
87. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006; 9: 425-434.
88. Kennedy KM, Dewhirst MW. Tumor metabolism of lactate: The influence and therapeutic potential for MCT and CD147 regulation. Future Oncol 2010; 6: 127-148.
89. Chatham JC, Des Rosiers C, Forder JR. Evidence of separate pathways for lactate uptake and release by the perfused rat heart. Am J Physiol Endocrinol Metab 2001; 281: E794-E802.
90. Bonen A. Lactate transporters (MCT proteins) in heart and skeletal muscles. Med Sci Sports Exerc 2000; 32: 778-789.
91. Hussien R, Brooks GA. Mitochondrial and plasma membrane lactate transporter and lactate dehydrogenase isoform expression in breast cancer cell lines. Physiol Genomics 2011; 43: 255-264.
92. Brooks GA, Dubouchaud H, Brown M, Sicurello JP, Butz CE. Role of mitochondrial lactate dehydrogenase and lactate oxidation in the intracellular lactate shuttle. Proc Natl Acad Sci USA 1999; 96: 1129-1134.
93. Sivridis E, Giatromanolaki A, Koukourakis MI. Proliferating fibroblasts at the invading tumour edge of colorectal adenocarcinomas are associated with endogenous markers of hypoxia, acidity, and oxidative stress. J Clin Pathol 2005; 58: 1033-1038.
94. Pavlides S, Whitaker-Menezes D, Castello-Cros R, et al. The reverse Warburg effect aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009; 8: 3984-4001.
95. Liu PS, Rudick M, Anderson RGW. Multiple functions of caveolin-1. J Biol Chem 2002; 277: 41295-41298.
96. Witkiewicz AK, Dasgupta A, Sotgia F, et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 2009; 174: 2023-2034.
97. Sloan EK, Ciocca DR, Pouliot N, et al. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol 2009; 174: 2035-2043.
98. Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, et al. Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle 2011; 10: 1772-1783.
99. Martinez-Outschoorn UE, Prisco M, Ertel A, et al. Ketones and lactate increase cancer cell "stemness", driving recurrence, metastasis and poor clinical outcome in breast cancer. Cell Cycle 2011; 10: 1271-1286.
100. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose invivo-High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33: 1972-1980.
101. Poettgen C, Theegarten D, Eberhardt W, et al. Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer. Oncology 2007; 73: 316-323.
102. Roiniotis J, Dinh H, Masendycz P, et al. Hypoxia prolongs monocyte/macrophage survival and enhanced glycolysis is associated with their maturation under aerobic conditions. J Immunol 2009; 182: 7974-7981.
103. Jones RG, Thompson CB. Revving the engine: Signal transduction fuels T cell activation. Immunity 2007; 27: 173-178.
104. Grillon E, Farion R, Fablet K, et al. The spatial organization of proton and lactate transport in a rat brain tumor. PLoS ONE 2011; 6: e17416, 1-9.
105. Kuchiiwa T, Nio-Kobayashi J, Takahashi-Iwanaga H, Yajima T, Iwanaga T. Cellular expression of monocarboxylate transporters in the female reproductive organ of mice: Implications for the genital lactate shuttle. Histochem Cell Biol 2011; 135: 351-360.